Abstract Details

<< Back to Detailed Agenda

9/25/2018  |   8:30 AM - 9:30 AM   |  Emerald Ballroom I/II

Discussion Revisited: Is Universal Newborn CMV Screening Good Public Health Policy?

This will be a point-counterpoint panel exploring the pros and cons of universal CMV screening. Each participant will be given 4-5 questions in advance to prepare a one-minute answer. Following each prepared answer, one colleague may make a thirty-second response. The original presenter may respond for 30 sec. (10-15 minutes per question total, 4-5 questions)

  • To understand the reasons for newborn screening for congenital CMV
  • To understand how screening for congenital CMV infection conforms to current guidelines for newborn screening

Presentation:
This presentation has not yet been uploaded.

Handouts:
No handouts have been uploaded.


Pablo Sanchez (Primary Presenter,Author), pablo.sanchez@nationwidechildrens.org;
n/a

      ASHA DISCLOSURE:

Financial - Receives Grants,Other financial benefit for Membership on advisory committee or review panels from MedImmune/AstraZeneca.   Receives Grants for Other activities from Merck.   Receives Other financial benefit for Membership on advisory committee or review panels from Sanofi-Pasteur.  

Nonfinancial - No relevant nonfinancial relationship exists.


      AAA DISCLOSURE:

Financial - Receives support from Medimmune-AstraZeneca Sanofi Pasteur Merck.  




Sheila Dollard (Co-Presenter), sgd5@cdc.gov;
Sheila Dollard earned her PhD in Biochemistry in 1991 from the University of Rochester Medical Center, Rochester. Her research focused on gene transcription and tissue specificity of human papillomaviruses. From 1992-1995 she was a post-doctoral fellow studying HIV gene transcription and pathogenesis in the Department of Microbiology at the University of Rochester. From 1995-1997 she served as Instructor and Fellow in the Residency Program in Public Health Laboratory Microbiology at Strong Memorial Hospital. In 1998 Dr. Dollard joined the Centers for Disease Control and Prevention as Team Leader for Herpesvirus Diagnostic Development where her work has focused on HHV-8 (human herpesvirus 8) and CMV epidemiology and diagnostics for the past 16 years. Dr. Dollard has been a co-Investigator on numerous NIH grants for HHV-8 and CMV. She has authored and co-authored over 60 papers in peer-reviewed journals and has co-authored 4 book chapters for HHV-8 and CMV.

      ASHA DISCLOSURE:

Financial - No relevant financial relationship exists.

Nonfinancial - No relevant nonfinancial relationship exists.


      AAA DISCLOSURE:

Financial - Receives support from Centers for Disease Control and Prevention.  




William Rawlinson (Co-Presenter), w.rawlinson@unsw.edu.au;
Dr. William Rawlinson is the Director of Virology, Department of Microbiology SEALS, with a conjoint position in the Department of Infectious Diseases, Prince of Wales Hospital. He is Professor in the faculties of Medicine and Science at UNSW, currently supervising PhD students researching CMV diagnosis, CMV antiviral resistance in transplantation, and testing for blood borne viruses (BBV) in transplantation. He has studied CMV infection in different settings since completing his PhD in the molecular biology of CMV. Most recently these studies have been of the adverse consequences of CMV in at-risk populations, using in vitro models. The Diagnostic Virology Laboratory he heads provides a range of molecular assays for CMV including antiviral resistance testing, and most recently ganciclovir levels using mass spectrometry. He consults on viral infections and general infectious diseases at Prince of Wales, Sydney Children’s and the Royal Hospital for Women.

      ASHA DISCLOSURE:

Financial -

Nonfinancial -


      AAA DISCLOSURE:

Financial - No relevant financial relationship exists.




Kirstin Coverstone (Co-Presenter), kristin.coverstone@umn.edu;
EHDI Coordinator

      ASHA DISCLOSURE:

Financial -

Nonfinancial -


      AAA DISCLOSURE:

Financial - No relevant financial relationship exists.